Literature DB >> 20384866

Analysis of FcgammaRIIA cytoplasmic tail requirements in signaling for serotonin secretion: evidence for an ITAM-dependent, PI3K-dependent pathway.

A B Daniels1, R G Worth, R J Dickstein, J S Dickstein, T-H Kim-Han, M-K Kim, A D Schreiber.   

Abstract

The human Fc receptor, FcgammaRIIA, is known to mediate phagocytosis and endocytosis, yet the greatest numbers of these receptors are expressed on the surface of non-phagocytic platelets, where they are involved in serotonin secretion. FcgammaRIIA harbours three tyrosine (Y) residues within its cytoplasmic domain. Y1 is upstream of both Y2 and Y3, which are contained within an immunoreceptor tyrosine-based activation motif (ITAM), required for many signaling events. We have demonstrated that the two ITAM tyrosines are required for phagocytic signaling and that mutation of a single ITAM tyrosine decreases but does not abolish phagocytic signaling. Furthermore, we have identified that the YMTL motif is required for endocytosis. These observations suggest that FcgammaRIIA utilizes different sequences for various signaling events. Therefore, we investigated the sequence requirements for another important FcgammaRIIA-mediated signaling event, serotonin secretion, using Rat Basophilic Leukemia (RBL-2H3) cells transfected with wildtype (WT) FcgammaRIIA or mutant FcgammaRIIA. Stimulation of cells expressing WT FcgammaRIIA induced release of serotonin at a level 7-fold greater than that in nonstimulated WT FcgammaRIIA-transfected cells or nontransfected RBL cells. Mutation of either ITAM tyrosine (Y2 or Y3) to phenylalanine was sufficient to abolish serotonin secretion. Further, while inhibition of Syk with piceatannol blocked phagocytosis as expected, it did not inhibit serotonin secretion. Additionally, inhibition of phosphoinositol-3-kinase (PI3K) with wortmannin only had a partial effect on serotonin signaling, despite the fact that the concentrations used completely abolished phagocytic signaling. These data suggest that the requirements for serotonin secretion differ from those for phagocytosis mediated by FcgammaRIIA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20384866      PMCID: PMC2855141          DOI: 10.1111/j.1365-3083.2010.02369.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  27 in total

Review 1.  Fc receptor biology.

Authors:  M Daëron
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

2.  Syk activation initiates downstream signaling events during human polymorphonuclear leukocyte phagocytosis.

Authors:  E M Raeder; P J Mansfield; V Hinkovska-Galcheva; J A Shayman; L A Boxer
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

3.  Molecular dissection of Fc gamma receptor-mediated phagocytosis.

Authors:  Z K Indik; J G Park; S Hunter; M Mantaring; A D Schreiber
Journal:  Immunol Lett       Date:  1995-01       Impact factor: 3.685

4.  SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling.

Authors:  L O Beitz; D A Fruman; T Kurosaki; L C Cantley; A M Scharenberg
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

5.  Phosphatidylinositol 3,4,5-trisphosphate-dependent stimulation of phospholipase C-gamma2 is an early key event in FcgammaRIIA-mediated activation of human platelets.

Authors:  M P Gratacap; B Payrastre; C Viala; G Mauco; M Plantavid; H Chap
Journal:  J Biol Chem       Date:  1998-09-18       Impact factor: 5.157

6.  Inhibition of Fcgamma receptor-mediated phagocytosis by a nonphagocytic Fcgamma receptor.

Authors:  S Hunter; Z K Indik; M K Kim; M D Cauley; J G Park; A D Schreiber
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

Review 7.  Tyrosine phosphorylation and Fcgamma receptor-mediated phagocytosis.

Authors:  A Strzelecka; K Kwiatkowska; A Sobota
Journal:  FEBS Lett       Date:  1997-01-02       Impact factor: 4.124

8.  Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol.

Authors:  J M Oliver; D L Burg; B S Wilson; J L McLaughlin; R L Geahlen
Journal:  J Biol Chem       Date:  1994-11-25       Impact factor: 5.157

Review 9.  The molecular dissection of Fc gamma receptor mediated phagocytosis.

Authors:  Z K Indik; J G Park; S Hunter; A D Schreiber
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113

10.  Identification of FcgammaRIIa as the ITAM-bearing receptor mediating alphaIIbbeta3 outside-in integrin signaling in human platelets.

Authors:  Brian Boylan; Cunji Gao; Vipul Rathore; Joan C Gill; Debra K Newman; Peter J Newman
Journal:  Blood       Date:  2008-07-18       Impact factor: 22.113

View more
  4 in total

1.  FcγRIIa requires lipid rafts, but not co-localization into rafts, for effector function.

Authors:  Joshua A Vieth; Moo-kyung Kim; Daniel Glaser; Kaitlyn Stiles; Alan D Schreiber; Randall G Worth
Journal:  Inflamm Res       Date:  2012-09-04       Impact factor: 4.575

2.  Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation.

Authors:  Sanae Ben Mkaddem; Amaya Murua; Héloise Flament; Dimitri Titeca-Beauport; Carine Bounaix; Luca Danelli; Pierre Launay; Marc Benhamou; Ulrich Blank; Eric Daugas; Nicolas Charles; Renato C Monteiro
Journal:  Nat Commun       Date:  2017-08-15       Impact factor: 14.919

3.  Importance of Fc Receptor γ-Chain ITAM Tyrosines in Neutrophil Activation and in vivo Autoimmune Arthritis.

Authors:  Tamás Németh; Krisztina Futosi; Marcell Szabó; Petra Aradi; Takashi Saito; Attila Mócsai; Zoltán Jakus
Journal:  Front Immunol       Date:  2019-02-25       Impact factor: 7.561

4.  Fc gamma receptor IIa suppresses type I and III interferon production by human myeloid immune cells.

Authors:  Melissa Newling; Willianne Hoepel; Lisa T C Vogelpoel; Marieke H Heineke; Johan A van Burgsteden; Esther W M Taanman-Kueter; Dirk Eggink; Taco W Kuijpers; Tim Beaumont; Marjolein van Egmond; Martien L Kapsenberg; Dominique L P Baeten; Jeroen den Dunnen; Esther C de Jong
Journal:  Eur J Immunol       Date:  2018-09-14       Impact factor: 5.532

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.